No Effect of Dose Adjustment to the CYP2D6 Genotype in Patients With Severe Mental Illness

Anne B. Koopmans*, David J. Vinkers, Igmar T. Poulina, Petra J. A. Gelan, Ron H. N. van Schaik, Hans W. Hoek, Peter N. van Harten

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

3 Citations (Web of Science)
Original languageEnglish
Article number349
Number of pages9
JournalFrontiers in Psychiatry
Volume9
DOIs
Publication statusPublished - 7 Aug 2018

Keywords

  • CYP2D6
  • severe mental illness (SMI)
  • guidelines
  • dose adjustment
  • genotyping
  • psychopharmacology
  • personalized medicine
  • CURACAO EXTRAPYRAMIDAL SYNDROMES
  • TARDIVE-DYSKINESIA
  • RATING-SCALE
  • PERSONALIZED MEDICINE
  • INDUCED AKATHISIA
  • SCHIZOPHRENIA
  • PHARMACOGENETICS
  • ANTIPSYCHOTICS
  • 2D6
  • POLYMORPHISMS

Cite this